In this review, we retrace the history of PSMA-target therapy and the role and and the main characteristics of the trials that led to Food and Drug Administration (FDA) approval of [177Lu]Lu-PSMA-617 as a therapeutic agent for metastatic PCa. This evidence concerns the gene FOLH1 and posterior cortical atrophy.